When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.
In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
For people who don’t read much English, following prescription labels can be a guessing game. Those who guess wrong can end up hurt by the medication that was supposed to help them. Even worse, they can end up hospitalized.
Senators got their first opportunity Tuesday to prod drugmakers about the wallet-emptying prices they charge for prescription drugs.
Oregon lawmakers have heard more than a dozen bills so far this session on the pharmaceutical industry, many attempting to address skyrocketing costs.
A rare scene of drama erupted in a House health care committee hearing on Tuesday as the chair and a lobbyist for the pharmaceutical industry clashed over a fairly straightforward bill that would require greater transparency on the part of drug manufacturers.
A two-decade surge in opioid overdose deaths has prompted health officials, addiction specialists and the federal government to declare opioid addiction a public health emergency.
California Gov. Gavin Newsom says he’s done waiting for the federal government to curtail the rising cost of prescription drugs.
Newsom has his own plan to ease that financial burden — one he hopes other states can join or replicate.